Related Experiment Videos
Isoprinosine in multiple sclerosis treatment: a preliminary study
Schweizer Archiv Fur Neurologie, Neurochirurgie Und Psychiatrie = Archives Suisses De Neurologie, Neurochirurgie Et De Psychiatrie
|January 1, 1982
Summary
This study investigated Isoprinosine for multiple sclerosis (MS) treatment. Results showed no significant clinical improvement in MS patients compared to prednisone, indicating limited efficacy for this immunomodulatory drug.
Area of Science:
- Immunology
- Neurology
- Pharmacology
Background:
- Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system.
- Cellular immunity plays a role in the pathogenesis of MS.
- Isoprinosine is an immunomodulatory agent that enhances cellular immunity.
Purpose of the Study:
- To evaluate the efficacy of Isoprinosine in patients with multiple sclerosis.
- To assess the impact of Isoprinosine on the clinical course and cerebrospinal fluid (CSF) IgG profile in MS patients.
Main Methods:
- A 60-day therapeutic trial of Isoprinosine in 11 MS patients.
- Evaluation using Kurtzke's Disability Status Scale before therapy, at 60 days, and 14 months post-therapy.
- Comparison with a control group of 11 MS patients treated with prednisone.
- CSF examination for IgG oligoclonal bands and IgG profile analysis.
Main Results:
- No significant difference in the clinical course of multiple sclerosis was observed between the Isoprinosine and prednisone groups.
- Cerebrospinal fluid (CSF) examination revealed persistent IgG oligoclonal bands in all patients.
- No modifications in the CSF IgG profile were detected after Isoprinosine therapy.
Conclusions:
- Isoprinosine did not demonstrate significant clinical efficacy in treating multiple sclerosis over a 14-month follow-up period.
- The drug did not alter the CSF IgG profile in MS patients.
- Further research may be needed to explore other immunomodulatory strategies for MS management.